GRFS News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

GR

Mkt Cap

$5.20B

Volume

848.93K

Loading chart

GR

GRFSGrifois, S.A.

GRFS

Pay with—

Available Balance0.00

GR

Mkt Cap

$5.13B

Volume

848.93K

Next Earnings

N/A

Chart Earnings News About Dividends Insider Filings

European Human Biospecimen Market Forecasts Growth from $881.8M (2025) to $1.94B by 2035, Profiling Grifols, Logical Biological & Europa BiositeThe European human biospecimen market is projected to grow at an 8.24% CAGR from $881.8 million in 2025 to $1.94 billion by 2035, driven by increasing demand for precision medicine, oncology research, and expanding biobanks. Growth is supported by rising pharmaceutical R&D spending and EU-funded initiatives, though challenges include stringent GDPR regulations, high operational costs, and variability in consent frameworks across countries.GlobeNewswire Inc. · Sep 16, 2026

Intravenous Immunoglobulin Market Size Worth USD 30.83 Billion by 2035, Growing at 7.49% CAGR – SNS InsiderThe global intravenous immunoglobulin (IVIG) market is projected to grow from USD 14.98 billion in 2025 to USD 30.83 billion by 2035, at a CAGR of 7.49%. Growth is driven by expanding neurological indications, increased plasma collection capacity, and rising demand for immunoglobulin-based treatments. However, plasma supply dependency and a 100% U.S. tariff on imported IVIG products implemented in October 2025 pose significant constraints. North America leads the market, while Asia-Pacific shows the fastest growth.GlobeNewswire Inc. · Sep 10, 2026

[Latest] Global Botulinum Toxin in Urology Market Size/Share Worth USD 1.98 Billion by 2035 at a 6.08% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)The global botulinum toxin in urology market is projected to grow from USD 1.1 billion in 2025 to USD 1.98 billion by 2035, at a CAGR of 6.08%. Growth is driven by increasing prevalence of urological disorders, aging populations, preference for minimally invasive treatments, and advancements in injection techniques. OnabotulinumtoxinA (Botox) leads the market, with overactive bladder being the largest application segment.GlobeNewswire Inc. · Jul 22, 2026

Hepatic Encephalopathy Market Set for Growth at a 1.2% CAGR Through 2036, Driven by Emerging Therapies and Rising Disease Burden | DelveInsightThe hepatic encephalopathy market is projected to grow at 1.2% CAGR through 2036, valued at USD 900 million in 2025. Growth is driven by rising prevalence of chronic liver diseases, improved early diagnosis awareness, and emerging therapies from companies like Vedanta Biosciences, Yaqrit Discovery Ltd, and others. The US dominates with 60% market share, with approximately 210,000 prevalent cases across the 7MM in 2025.GlobeNewswire Inc. · May 4, 2026

Ban Grifols and return plasma collection to Canadian Blood Services and Héma-Québec, say health care advocatesCanadian health care advocates are calling for the closure of Grifols plasma collection facilities and a public takeover following two deaths in Winnipeg linked to plasma sales, a third lawsuit for kidney damage, and Health Canada reports of non-compliance at four additional Grifols sites.GlobeNewswire Inc. · Mar 30, 2026

Pegasys (Roche, pharmaand) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035FPegasys market is poised for significant growth driven by rising hepatitis B prevalence, increasing healthcare spending, and expansion into oncology and hematology indications. However, the market faces headwinds from the rise of direct-acting antivirals and tariff-related cost pressures. North America leads in market share while Asia-Pacific is expected to grow fastest.GlobeNewswire Inc. · Mar 10, 2026

Plasbumin-5 (Grifols Therapeutics) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035FThe global Plasbumin-5 market is experiencing significant growth driven by rising surgical procedures, burn injuries, and expanding critical care infrastructure. North America leads the market while Asia-Pacific is the fastest-growing region. Grifols Therapeutics, the key market player, has strengthened its position through strategic partnerships, including a December 2023 collaboration with Haier Group to enhance distribution in China. Market growth is supported by innovations in plasma fractionation technologies and increased adoption in liver and cardiac care.GlobeNewswire Inc. · Mar 10, 2026

Global Blood Plasma Derivatives Market Size Projected to Reach $104.30 Billion by 2033; Immunoglobulins Drive Robust 9.08% CAGR – SNS InsiderThe global blood plasma derivatives market is expected to double from $52.16 billion in 2025 to $104.30 billion by 2033, growing at a 9.08% CAGR. Growth is driven by increasing immune deficiencies, hematological disorders, and neurological conditions, with immunoglobulins representing 41.28% of the market. North America leads with 39.57% market share, while Asia-Pacific is the fastest-growing region at 10.89% CAGR.GlobeNewswire Inc. · Feb 19, 2026

Plasma Derived Medicine Market to Reach USD 37.4 Billion by 2034, Growing at 8.05% CAGRThe global plasma derived medicine market is projected to grow from $17.24 billion in 2024 to $37.4 billion by 2034, driven by increasing demand for therapies treating rare and immune disorders, with North America currently dominating the market.GlobeNewswire Inc. · Aug 7, 2025

Orphan Designated Drugs Market Analysis: Key Trends, Players and Forecasts for Future GrowthThe report examines the trends shaping the orphan designated drugs market, including healthcare, technology, macroeconomic, and regulatory factors. It provides insights into leading players and future challengers across the value chain, as well as key drugs and markets.GlobeNewswire Inc. · Feb 3, 2025

to start trading

GR

GRFSGrifois, S.A.

GRFS

Pay with—

Available Balance0.00

Your PositionYou don't own any GRFS yet.

Related Tickers

Earnings

Dividends

Last · Jul 2Annual

Amount$0.0940

Yield1.23%

Annual$0.0940